Denali Ventures

Denali Ventures is an investment firm established in 1998 and located in Herzlia, Israel. The company focuses on financing innovative businesses in the healthcare sector, particularly those involved in biotechnology, genetics, pharmaceuticals, medical devices, and other health technologies. Denali Ventures aims to support the development of solutions that address significant disease entities and medical conditions, contributing to advancements in healthcare and improving patient outcomes.

Noam Karstaedt

President

6 past transactions

Fanplayr

Series A in 2016
Fanplayr is a prominent company specializing in online behavioral personalization and artificial intelligence, focused on enhancing user privacy. Headquartered in Palo Alto, California, with a global presence that includes offices in major cities across North America, South America, Europe, and Asia, Fanplayr offers a data analytics platform that provides real-time customer insights. This platform is designed to help businesses increase conversion rates and revenue by delivering personalized recommendations and improving lead collection. By leveraging analytic insights and targeting capabilities, Fanplayr enables companies to create engaging marketing campaigns that significantly boost conversion rates and positively impact their financial outcomes.

Gamida Cell

Series E in 2012
Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Gamida Cell

Series D in 2006
Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

HyperRoll

Series B in 2002
HyperRoll is a provider of data warehouse performance acceleration software, specializing in its Data Performance Management Suite. This suite enhances load times, query times, and throughput for data warehouses, enabling organizations to respond swiftly to changes in data and metadata while reducing overall costs. HyperRoll's innovative software architecture represents a significant advancement in managing business data performance. In addition to its core software offerings, the company also provides solutions across various sectors, including consumer products, retail, finance, supply chain, and customer relationship management. Furthermore, HyperRoll offers advisory, consulting, education, and technical support services to assist clients in maximizing the benefits of their data management strategies.

D Pharm

Series D in 2001
D-Pharm (TASE: DPRM) is a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. The Company’s particular area of interest is in developing innovative medicine for degenerative and age-related disorders.

HyperRoll

Series A in 2000
HyperRoll is a provider of data warehouse performance acceleration software, specializing in its Data Performance Management Suite. This suite enhances load times, query times, and throughput for data warehouses, enabling organizations to respond swiftly to changes in data and metadata while reducing overall costs. HyperRoll's innovative software architecture represents a significant advancement in managing business data performance. In addition to its core software offerings, the company also provides solutions across various sectors, including consumer products, retail, finance, supply chain, and customer relationship management. Furthermore, HyperRoll offers advisory, consulting, education, and technical support services to assist clients in maximizing the benefits of their data management strategies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.